CABO–CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV
Carmen Hidalgo Tenorio, M. Aguilera García, Ignacio de los Santos, A. Ruiz Sancho et autres
BACKGROUND: This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y. METHODS: A prospective, longitudinal, …
es (code pays fourni par la source)
0 citations
International Journal of Antimicrobial Agents